The 11 most recent market catalysts affecting $GCTK, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 24, 2026
Corporate Catalyst
Neutral
Impact 55
Glucotrack Prices $3.1M Offering Of Stock At $2.04/Share
This headline signals a capital raise for Glucotrack (GCTK). While securing funding is generally positive for a company's long-term viability, issuing new shares at $2.04, potentia…
Sep 24, 2026
Corporate Catalyst
Bullish
Impact 75
Glucotrack Stock Is Trending: Here's Why GCTK Jumped Over 80% After Hours
Glucotrack's subsidiary, Lokahi Therapeutics, secured its first external fee-for-service partnership with Innovate GBM, a nonprofit focused on glioblastoma research. This is signif…
Sep 8, 2026
Corporate Catalyst
Bullish
Impact 65
Glucotrack's Lōkahi Therapeutics Announces Expansion Of ai² Platform Into Three Divisions: ai² Pipeline, ai² Talent, And ai² Accelerator; Says Platform Now Spans 13 Universities, Has Evaluated More Than 45 Therapeutic Assets
This announcement indicates a significant strategic expansion for Glucotrack's Lōkahi Therapeutics, aiming to leverage AI for drug discovery and development. The expansion into 'Pi…
Aug 27, 2026
Corporate Catalyst
Neutral
Impact 75
Glucotrack Announces 1-For-15 Reverse Stock Split Effective August 31
A 1-for-15 reverse stock split for Glucotrack (GCTK) is a significant corporate action, primarily undertaken to increase the per-share price and avoid delisting from exchanges like…
Jul 30, 2026
Corporate Catalyst
Bullish
Impact 75
GlucoTrack (GCTK) Stock Surges Over 70% After Hours: Why is it Moving?
GlucoTrack (GCTK) shares surged over 70% after its subsidiary, Lokahi Therapeutics, announced a simplified single-injection strategy for its LT-100 program, which treats osteoarthr…
Jul 29, 2026
Corporate Catalyst
Bullish
Impact 65
GlucoTrack's Subsidiary, Lōkahi Therapeutics, Advances LT-100 Development Strategy Toward Single-Injection Administration; FDA Type C Meeting and Nonclinical Study Advance Strategy To Transition LT-100 From 15 Injections To One
Lōkahi Therapeutics, a subsidiary of GlucoTrack (GCTK), announced progress in simplifying the administration of its drug candidate, LT-100, from 15 intradermal injections to a sing…
Jul 17, 2026
Corporate Catalyst
Bullish
Impact 85
GlucoTrack (GCTK) Stock Rallies 16% After Hours: Here's What Is Going On
GlucoTrack (GCTK) announced the completion of its merger with Lokahi Therapeutics, a significant corporate restructuring event. This transaction is a major catalyst as it fundament…
Jul 15, 2026
Corporate Catalyst
Bullish
Impact 75
Glucotrack (GCTK) Stock Is Trending Overnight — Here’s Why it Spiked Over 69% in After-Hours Session
Glucotrack (GCTK) experienced a significant overnight spike due to the announcement of a patent allowance for its continuous blood glucose monitoring (CBGM) technology. This patent…
Jul 14, 2026
Corporate Catalyst
Bullish
Impact 95
GlucoTrack Completes Its Strategic Business Combination With Lōkahi Therapeutics; Transaction Is Structured Such That Lōkahi Therapeutics Becomes The Operating And Controlling Business Of The Combined Company, Leveraging Glucotrack’s Public Market Platform To Support Long-Term Growth And Access To Capital
Glucotrack (GCTK) has completed a reverse merger with Lōkahi Therapeutics, where Lōkahi effectively takes over the public company. This is a significant event for GCTK as it fundam…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.